Metaba
Metaba is a preclinical biopharmaceutical company developing novel therapies for infectious diseases. The company focuses on creating first-in-class, orally bioavailable, oxysterol-based compounds with bactericidal activity against drug-resistant pathogens. This platform aims to address antimicrobial resistance by advancing safer and more efficacious antibiotic solutions.
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
The increasing prevalence of drug-resistant bacteria poses a significant threat to global health, demanding new and more effective antibiotic solutions. Existing treatments for infectious diseases, such as Tuberculosis, are often inadequate, highlighting the urgent need for novel therapeutic approaches.
Solution
Metaba is a preclinical biopharmaceutical company developing first-in-class, orally bioavailable, oxysterol-based compounds with bactericidal activity against drug-resistant bacteria. Their approach combines metabolomics analysis with computer-aided drug discovery to identify and develop life-saving therapies for infectious diseases. Metaba's platform enables rapid adaptation to multiple indications, addressing the growing global health crisis of antimicrobial resistance by advancing safer and more efficacious antibiotic solutions. The company collaborates with pharmaceutical companies and research institutions to accelerate the development of these innovative therapies.
Target Audience
The primary target audience includes patients suffering from infectious diseases, particularly those with drug-resistant bacterial infections, as well as pharmaceutical companies and research institutions seeking innovative therapeutic solutions.
Features
- Semi-synthetic, orally bioavailable, oxysterol-based compounds with bactericidal activity.
- Advanced metabolomics analysis platform for identifying drug targets.
- Computer-aided drug discovery methodologies for efficient therapeutic development.
- Focus on developing therapies for drug-resistant Mycobacterium tuberculosis (Mtb) and other bacteria.
- Hypothesis-driven strategies for developing life-saving therapies for infectious diseases.